Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)
Alimentary Pharmacology & Therapeutics2020Vol. 51(5), pp. 534–543
Citations Over TimeTop 10% of 2020 papers
Toshihisa Takeuchi, Takahisa Furuta, Yasuhiro Fujiwara, Mitsushige Sugimoto, Kunio Kasugai, Motoyasu Kusano, Hiroyuki Okada, Takahiro Suzuki, Tomohiro Higuchi, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Akinari Sawada, Fumio Tanaka, Satoshi Harada, Ota K, Yuichi Kojima, Masaki Murata, Yasuhiro Tamura, Yasushi Funaki, Osamu Kawamura, Yuki Okamoto, Kazuma Fujimoto, Kazuhide Higuchi
Abstract
Compared with 2-4 times the standard daily dose of R, V20 exerts a more potent and durable acid-inhibitory effect. Trial identifier: UMIN000022198 (www.umin.ac.jp/ctr/index.htm).
Related Papers
- → Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice(2016)6 cited
- → Review article: the pharmacology of rabeprazole(1999)82 cited
- → Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual‐dose proton pump inhibitor: Acotiamide plus usual‐dose proton pump inhibitor versus double‐dose proton pump inhibitor(2017)20 cited
- → Effects of CYP2C19 gene polymorphism on cure rates for Helicebacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin, and clarithromycin(2001)2 cited
- Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin and clarithromycin in Japan(2001)